Biologics Contract Development Market Size Is Projected To Reach $11.2 Billion By 2027

The global biologics contract development market size is expected to reach USD 11.2 billion by 2027, according to a new report by Grand View Research, Inc., expanding at a CAGR of 8.8% over the forecast period. The market comprises of organizations that offer services such as the development of cell lines, upstream and downstream processes, analytical methods, and formulations. These organizations specialize in developing and manufacturing stable cell lines that are extensively used in a number of important applications including drug screening, gene functional studies, and biologics production. The market is segmented on the basis of biological source, product service (Upstream and Downstream), and disease indication. Factors such as increasing adoption of advanced technologies for biologic development, favorable environment for clinical trials in developing countries, and an increase in outsourcing of R&D activities are paving way for the growth of the market.

Growing M&A and collaboration activities between biopharma companies and CDOs are yet another factor assisting in market growth, allowing more financial stability and amalgamation of advanced and specialized technologies. For instance, in February 2020, LakePharma, Inc., and NJ Biopharmaceuticals LLC, a CRO, providing integrated chemistry and biology services, announced a strategic alliance to offer streamlined Antibody-Drug Conjugate (ADC) development solutions for biotechnology and pharmaceutical sectors. Many biopharma and pharma companies are increasingly looking for outsourcing their activities as it helps accelerate workflow (speed) of the company, provides unique specialized services, decreases drug manufacturing costs, and provides expertise. These factors are expected to boost the biologics contract development and manufacturing organization market growth in the coming years.

Full Research Report On Biologics Contract Development Market Visit Here: https://www.grandviewresearch.com/industry-analysis/biologics-contract-development-market

Biologics Contract Development Market Report Highlights

• Mammalian source emerged as the largest product segment in 2019, as the majority of research activities are being carried out using mammalian cell lines
• The process development segment is expected to witness the highest CAGR over the forecast period, as many companies are opting to outsource for production of recombinant proteins and Monoclonal Antibodies (MABs)
• North America dominated the market in 2019. Increase in strategic acquisitions and partnerships and rise in demand for specialized testing services are likely to have a positive impact on the market
• In Asia Pacific, the market is expected to encounter the highest CAGR over the forecast period.

Request a Sample Copy of the Report @ https://www.grandviewresearch.com/industry-analysis/biologics-contract-development-market/request/rs1

Biologics Contract Development Market Segmentation

Grand View Research has segmented the global biologics contract development market on the basis of source, product service type, disease indication, and region:

Biologics Contract Development Source Outlook (Revenue, USD Million, 2016 - 2027)

• Microbial
• Mammalian
• Others

Biologics Contract Development Product Service Type Outlook (Revenue, USD Million, 2016 - 2027)

• Cell Line Development
• Microbial
• Mammalian
• Others
• Process Development
• Upstream

• Microbial
• Mammalian
• Others
• Downstream
• Impurity, isolation, & identification
• Physicochemical characterization
• Pharmaceutical analysis
• Others
• By Product
• MABs
• Recombinant proteins
• Others
• Others

Biologics Contract Development Disease Indication Outlook (Revenue, USD Million, 2016 - 2027)

• Oncology
• Immunological disorders
• Cardiovascular disorders
• Hematological disorders
• Others

Biologics Contract Development Regional Outlook (Revenue, USD Million, 2016 - 2027)

• North America
• The U.S.
• Canada
• Europe
• The U.K.
• Germany
• France
• Italy
• Spain
• Asia Pacific
• India
• Japan
• China
• Australia
• South Korea
• Latin America
• Brazil
• Mexico
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

List of Key Players of Biologics Contract Development Market

• WuXi Biologics
• Abzena Ltd.
• Fujifilm Diosynth Biotechnologies
• KBI Biopharma
• AGC Biologics
• SE Thermo Fisher (Patheon)
• LakePharma
• Genscript Biotech Corporation
• Bionova Scientific
• Boehringer Ingelheim BioXcellence
• STC Biologics, Inc.

About Grand View Research        

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more info visit @ https://www.grandviewresearch.com